Position in AKTS
as of Mar 31, 2026
· filed May 15, 2026
Position Value
$6,912,320
New position
Shares Held
386,379
first reported quarter
Ownership
0.699%
of shares outstanding
% of Portfolio
0.00%
of 13F equity value
Holder Rank
—
not a current holder
Holding Since
Mar 2026
1 quarter on record
Voting authority
Sole 99%
Shared 0%
None 1%
Position in Biotechnology
Healthcare · as of Mar 31, 2026FMR LLC holds $49,682,018,247 across 354 Biotechnology names. AKTS ranks #157 (0.0% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
14,579,166 | $4,823,808,652 | |
| 2 | ARGX |
Argenx SE
|
4,991,034 | $3,644,702,577 | |
| 3 | MRNA |
Moderna, Inc.
|
45,672,024 | $2,320,138,818 | |
| 4 | ROIV |
Roivant Sciences Ltd.
|
77,981,253 | $2,160,080,705 | |
| 5 | INSM |
INSMED Inc
|
13,160,167 | $2,151,950,504 | |
| 6 | IONS |
Ionis Pharmaceuticals Inc
|
24,556,637 | $1,843,957,869 | |
| 7 | RPRX |
Royalty Pharma plc
|
25,152,242 | $1,206,553,046 | |
| 8 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,518,192 | $1,173,015,865 |
All Filings in AKTS
Export CSV
1 filing row on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-03-31 | $6,912,320 | 386,379 | Shares | Defined | 2026-05-15 | |
| No filing history on record for this holder in this stock. | ||||||